Opendata, web and dolomites

PEVIA SIGNED

PAN EBOLA VACCINE INNOVATIVE APPROACH – Sofia ref.: 116088

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PEVIA project word cloud

Explore the words cloud of the PEVIA project. It provides you a very rough idea of what is the project "PEVIA" about.

historic    viruses    infection    discovery    monovalent    drugs    treatment    prevention    antiviral    fevers    species    safe    shown    outbreak    trials    rural    dangerous    models    outbreaks    pattern    lethal    human    protective    people    microorganisms    combined    proportions    event    spurred    global    zaire    safety    efficacy    clinical    causing    approved    protect    vector    primates    risk    immunogenicity    ebola    family    public    hence    strains    vesicular    stomatitis    severity    immune    endemic    humans    threat    magnitude    hemorrhagic    isolated    vaccines    health    demonstrating    mostly    reached    strain    fatality    attract    filoviridae    induce    preventive    1976    world    candidates    infections    did    patients    east    ebov    virus    rapid    vaccine    highest    lasting    africa    larger    confined    gained    caring    caused    severe    readily    spread    underscoring    sporadic    west    serious    regions    disease    occurred    took    healthcare    2014    central    animal    workers   

Project "PEVIA" data sheet

The following table provides information about the project.

Coordinator
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS 

Organization address
address: 3 AVENUE VICTORIA
city: PARIS
postcode: 75000
website: http://www.aphp.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.pevia-ebola.eu
 Total cost 17˙731˙397 €
 EC max contribution 6˙189˙570 € (35%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-08-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2023-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) coordinator 1˙297˙406.00
2    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 1˙040˙108.00
3    OLIGOVAX FR (PARIS) participant 863˙000.00
4    CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE FR (LILLE) participant 603˙125.00
5    UNIVERSITE D'ABOMEY-CALAVI BJ (ABOMEY CALAVI) participant 566˙312.00
6    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 533˙332.00
7    IFAKARA HEALTH INSTITUTE TRUST TZ (DAR ES SALAAM) participant 502˙000.00
8    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 273˙650.00
9    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 246˙887.00
10    BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN DE (HAMBURG) participant 182˙500.00
11    HEINRICH-PETTE INSTITUT LEIBNIZ INSTITUT FUER EXPERIMENTELLE VIROLOGIE DE (HAMBURG) participant 81˙250.00
12    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 0.00
13    EXCELLGENE SA CH (MONTHEY) participant 0.00
14    VAXEAL RESEARCH FR (EVRY) participant 0.00

Map

 Project objective

Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discovery in 1976, five different Ebola virus species have been isolated and over 20 sporadic EBOV outbreaks have occurred, mostly confined to rural areas in East and Central Africa. Hence the disease did not attract much global attention. However, the 2014 Ebola outbreak in West Africa, caused by Ebola Zaire strain, gained widespread attention as it took a different pattern and has reached historic proportions, characterized by a rapid and larger spread beyond Africa, and a greater magnitude than all the other outbreaks combined, underscoring its serious threat to the public health. No vaccines or antiviral drugs currently approved for prevention or treatment of Ebola infections in humans. However, the severity of the recent Ebola outbreak and the potential risk of global spread, has spurred research for the rapid development of safe and effective preventive Ebola vaccine. Such a vaccine, that can rapidly induce strong and long-lasting protective immune responses against all main Ebola strains and that can be readily produce and deployed in the field, is needed to protect people in endemic regions in an event of an outbreak but also to protect healthcare workers caring for Ebola patients, who are at the highest risk of infection even before an outbreak can be identified.

A number of EBOV vaccine candidates are under development and some have been shown to induce protective immune responses against lethal Ebola virus infection in different animal models, including non-human primates. In response to the recent Ebola outbreak, three main promising monovalent vector-based vaccines are being investigated in human clinical trials, demonstrating their safety and immunogenicity and the potential efficacy of a Vesicular Stomatitis Virus-based vaccine

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PEVIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PEVIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RADAR-AD (2019)

Remote Assessment of Disease and Relapse – Alzheimer’s Disease

Read More  

FAIRplus (2019)

FAIRplus

Read More  

STOPFOP (2019)

Saracatinib Trial tO Prevent FOP

Read More